CCTV.com News (News 30 minutes): The reporter learned from the Ministry of Science and Technology that significant progress has been made in the research of a therapeutic hepatitis B vaccine independently developed in my country. The test results show that the vaccine can clear the virus in animals, that is to say It is possible to convert the human hepatitis virus from positive to negative.
Professor Wu Yuzhang of the Third Military Medical University and his scientific research team have conducted scientific research on therapeutic hepatitis B vaccines for 17 years. They have creatively proposed treatment strategies for hepatitis B in the world and screened out vaccines that can stimulate hepatitis B. Vaccine for virus cell immunity, and applied for patent protection for 72 core technologies.
Professor Wu Yuzhang of the Third Military Medical University: Because the hepatitis B virus exists within cells, the virus in the cells must be removed to achieve the purpose of eliminating the virus. Through animal experiments, we have Preliminary evidence shows that it can clear viruses in the body, which means it is possible that it will have a similar effect in the human body.
my country is an area with a high incidence of hepatitis B. There are more than 130 million hepatitis B virus carriers and more than 39 million hepatitis B patients nationwide. It is understood that the therapeutic hepatitis B vaccine independently developed in my country has not only completed animal testing, but also completed a phase I clinical study. The results show that the vaccine not only has good safety, but also can produce immunity to the hepatitis B virus in the human body.
Professor Wu Yuzhang of the Third Military Medical University: We are currently conducting phase II clinical trials. We are planning to do 100 pairs of patients, hoping to initially confirm its effectiveness.
According to reports, the current therapeutic hepatitis B vaccine is only a research result. After the completion of the second phase of clinical trials, phase three clinical trials will be conducted on more than 500 people. To further prove the effectiveness and safety of the vaccine. After the completion of Phase III clinical trials and approval by relevant departments, it can be produced and marketed.